miércoles, 23 de noviembre de 2022

FDA Approves IMJUDO (Tremelimumab-actl) in Combination with Durvalumab for the Treatment of Adult Patients with Unresectable Hepatocellular Carcinoma (uHCC)

label

No hay comentarios:

Publicar un comentario